

Type of the Paper (Abstract)

Development of therapies for the two sides of the cornea[†]

Graziella Pellegrini¹, Eleonora Maurizi¹

¹ Centre for Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy;

* Correspondence: graziella.pellegrini@unimore.it; eleonora.maurizi@unimore.it

† Presented at the title, place, and date.

Abstract:

The clearness of the cornea is essential for visual acuity and is guaranteed by limbal stem cell regeneration of the outer specialized epithelium and by the integrity of the inner corneal endothelium. Limbal Stem Cell Deficiency (LSCD) leads to multiple corneal abnormalities including visual loss. Autologous Cultivated Limbal Stem Cell Transplantation is the first stem cell treatment for LSCD, approved at EU level. Here we present the results from the first EU multicenter clinical trial on EU citizens and a following step for the future restoration of other corneal areas, specifically the corneal endothelium.

Keywords: corneal epithelium; limbal stem cell deficiency; EU multicenter clinical trial; corneal endothelium

Citation: Pellegrini, G.; Maurizi, E.

Development of therapies for the two sides of the cornea. *Biol. Life Sci. Forum* **2022**, *2*, x.

<https://doi.org/10.3390/xxxxx>

Academic Editor:

Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).